Document is current
Any future updates will be listed below
-
Authors
Clarke, Julia R
Lyra e Silva, Natalia M
Figueiredo, Claudia P
Frozza, Rudimar L
Ledo, Jose H
Beckman, Danielle
Katashima, Carlos K
Razolli, Daniela
Carvalho, Bruno M
Frazão, Renata
Silveira, Marina A
Ribeiro, Felipe C
Bomfim, Theresa R
Neves, Fernanda S
Klein, William L
Medeiros, Rodrigo
LaFerla, Frank M
Carvalheira, Jose B
Saad, Mario J
Munoz, Douglas P
Velloso, Licio A
Ferreira, Sergio T
De Felice, Fernanda G
-
Funding
Funding for this research was provided by:
Human Frontiers Science Program
National Institute for Translational Neuroscience
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP2012/12202‐4)
Canadian Institutes for Health Research
Canada Research Chair Program
CAPES
- License Information
-
More Information
Article History
Received: 30 April 2014
Revised: 12 December 2014
Accepted: 17 December 2014
First Online: 23 January 2015
Conflict of interest
: WLK is a cofounder of Acumen Pharmaceuticals, which has been licensed by Northwestern University to develop ADDL technology for Alzheimer's therapeutics and diagnostics.
